Ad Comm review set for Dynavax's HEPLISAV-B; shares ahead 17% premarket

|About: Dynavax Technologies C... (DVAX)|By:, SA News Editor

Dynavax (NASDAQ:DVAX) is up 17% premarket on light volume in response to its announcement that the FDA's Vaccines and Related Biological Products Advisory Committee will review its marketing application for hepatitis B vaccine candidate HEPLISAV-B on July 28.

The agency's action date (PDUFA) remains unchanged on August 10.